COBIMETINIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H21F3IN3O2
Molecular Weight	531.31
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of COBIMETINIB

Structure Search

SMILES

[H][C@]1(CCCCN1)C2(O)CN(C2)C(=O)C3=C(NC4=CC=C(I)C=C4F)C(F)=C(F)C=C3

InChI

InChIKey=BSMCAPRUBJMWDF-KRWDZBQOSA-N

InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H21F3IN3O2
Molecular Weight	531.31
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 21:20:54 UTC 2023` Edited by `admin` on `Fri Dec 15 21:20:54 UTC 2023`
Record UNII	ER29L26N1X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COBIMETINIB

Official Name

English

COBIMETINIB [USAN]

Common Name

English

XL 518

Common Name

English

GDC-0973

Code

English

XL-518

Common Name

English

((3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)PHENYL)(3-HYDROXY-3-((2S)-PIPERIDIN-2-YL)AZETIDIN-1-YL)METHANONE

Common Name

English

cobimetinib [INN]

Common Name

English

XL518

Common Name

English

Cobimetinib [WHO-DD]

Common Name

English

GDC 0973

Common Name

English

RG-7420

Code

English

COBIMETINIB [MI]

Common Name

English

RG 7420

Code

English

RG7420

Code

English

METHANONE, (3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)PHENYL)(3-HYDROXY-3-((2S)-2-PIPERIDINYL)-1-AZETIDINYL)-

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

L01XE38

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

FDA ORPHAN DRUG

752820

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

NCI_THESAURUS

C129825

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

NDF-RT

N0000175605

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

FDA ORPHAN DRUG

419513

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

NCI_THESAURUS

C69145

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

Code System Code Type Description

ChEMBL

CHEMBL2146883

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

NDF-RT

N0000175082

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

Kinase Inhibitors [MoA]

CHEBI

90853

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

NCI_THESAURUS

C68923

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

DAILYMED

ER29L26N1X

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

RXCUI

1722365

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

RxNorm

PUBCHEM

16222096

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

EVMPD

SUB122319

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

INN

9645

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

FDA UNII

ER29L26N1X

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

USAN

ZZ-137

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

MERCK INDEX

m11872

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

CHEBI

90851

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

LACTMED

Cobimetinib

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

DRUG CENTRAL

5046

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

ChEMBL

CHEMBL3330650

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

SMS_ID

100000144958

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

DRUG BANK

DB05239

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

CAS

934660-93-2

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

WIKIPEDIA

Cobimetinib

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

EPA CompTox

DTXSID60239435

Created by admin on Fri Dec 15 21:20:55 UTC 2023 , Edited by admin on Fri Dec 15 21:20:55 UTC 2023

PRIMARY

Related Record Type Details


					ER29L26N1X

EXCRETED UNCHANGED

Comments:

Amount recovered in the feces of healthy subjects after a single dose of 20 mg Cobimetinib

Qualification:

FECAL

Amount:


					CTZ3P20I6M

DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1

TARGET -> INHIBITOR


					8E4LAA4357

CYTOCHROME P450 2D6

METABOLIC ENZYME -> INHIBITOR

Comments:

Cobimetinib is a reversible inhibitor of CYP3A4 and CYP2D6 in vitro.

Interaction Type:

REVERSIBLE


					6EXI96H8SV

COBIMETINIB FUMARATE

SALT/SOLVATE -> PARENT


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Comments:

Cobimetinib is a reversible inhibitor of CYP3A4 and CYP2D6 in vitro.

Interaction Type:

REVERSIBLE


					ER29L26N1X

EXCRETED UNCHANGED

Comments:

Amount recovered in the urine of healthy subjects after a single dose of 20 mg Cobimetinib

Qualification:

URINE

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Comments:

Cobimetinib is a time-dependent inhibitor of CYP3A4 in vitro.

Interaction Type:

TIME-DEPENDENT INHIBITION


					0M77ZW789J

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7

METABOLIC ENZYME -> SUBSTRATE


					2LN825UA70

(2S,3S,4S,5R,6S)-6-(1-(3,4-DIFLUORO-2-(2-FLUORO-4-IODO-ANILINO)BENZOYL)-3-((2S)-2-PIPERIDYL)AZETIDIN-3-YL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

CONJUGATE -> PARENT

Related Record Type Details


					N69Y48L5NP

(3,4-DIFLUORO-2-(2-FLUORO-4-IODO-ANILINO)PHENYL)-(3-HYDROXY-3-((2S)-1-OXOPIPERIDIN-1-IUM-2-YL)AZETIDIN-1-YL)METHANONE

METABOLITE -> PARENT


					TJS4VN7FAM

3-AZETIDINEPENTANOIC ACID, 1-(3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZOYL)-.DELTA.,3-DIHYDROXY-

METABOLITE -> PARENT


					2LN825UA70

(2S,3S,4S,5R,6S)-6-(1-(3,4-DIFLUORO-2-(2-FLUORO-4-IODO-ANILINO)BENZOYL)-3-((2S)-2-PIPERIDYL)AZETIDIN-3-YL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE INACTIVE -> PARENT


					6ER6X724KB

N-(3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZOYL)GLYCINE

METABOLITE -> PARENT

Comments:

Four hours after a Single Dose of 20 mg Cobimetinib in Healthy Subjects

Qualification:

PLASMA

Amount:


					YXZ9926HUV

L-SERINE, N-(3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZOYL)-

METABOLITE -> PARENT


					5A6V9RGK6M

2-(2-FLUORO-4-IODOANILINO)-3,4-DIFLUOROBENZOIC ACID

METABOLITE -> PARENT


					6ER6X724KB

N-(3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZOYL)GLYCINE

METABOLITE -> PARENT

Comments:

Glycine conjugate of the hydrolyzed product after a single dose of 20 mg Cobimetinib

Qualification:

URINE

Amount:


					5PJG2TV7UK

2-PIPERIDINONE, 6-(1-(3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZOYL)-3-HYDROXY-3-AZETIDINYL)-, (6S)-

METABOLITE -> PARENT

Related Record Type Details


					ER29L26N1X

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION ONCE DAILY DOSE

Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC